Since SSc-PAH progresses slowly whereas skin and lung involvements typically appear first, disease-modifying agents that modulate IL-17A and IL-6R are expected to use for the therapy for skin and pulmonary manifestations and may enable the initiation of treatment before the onset of SSc-PAH. Here, IL6R is linked to systemic sclerosis.